Aileron Launches Early-Stage Study For Chemoprotective Candidate In Lung Cancer Settings

Aileron Therapeutics Inc ALRN has initiated Phase 1b trial of ALRN-6924 as a chemoprotective agent to treat patients with non-small cell lung cancer undergoing chemotherapy.
Aileron plans to enroll 60 patients with advanced p53-mutated NSCLC undergoing treatment with first-line carboplatin plus pemetrexed with or without immune checkpoint inhibitors.
Aileron is developing ALRN-6924 to selectively protect healthy cells in patients to reduce or eliminate chemotherapy-induced side effects while preserving chemotherapy's attack on cancer cells.
Primary endpoints are the proportion of treatment cycles free of severe hematological and other toxicities.
An additional primary endpoint is the proportion of completed treatment cycles without chemotherapy dose reduction or without the use of growth factors or transfusions.
Aileron anticipates reporting the first interim safety data from the trial late in the fourth quarter of 2021 and full results in mid-2022.
Price Action: ALRN shares are up 3.77% at $1.30 during the market session on the last check Thursday.